Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.
Multiple Myeloma
DRUG: BT062
Dose limiting toxicity, On a weekly basis for the duration of the study|Maximum tolerated dose, About every 2 months for the duration of the study
Qualitative and quantitative toxicities, On a weekly basis for the duration of the study|Pharmacokinetics, On a weekly basis for the duration of the study|Anti-tumor activity, At the beginning of each treatment cycle
This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.